Last reviewed · How we verify
GCS Ramsay Santé pour l'Enseignement et la Recherche — Portfolio Competitive Intelligence Brief
3 marketed
0 filed
0 Phase 3
0 Phase 2
5 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Rachianesthesia | Rachianesthesia | marketed | Other | |||
| standard pain relievers | standard pain relievers | marketed | Nonsteroidal anti-inflammatory drug (NSAID) or analgesic | COX-1 and/or COX-2 enzymes (for NSAIDs); central pain pathways (for acetaminophen) | Pain Management | |
| C1 Inhibitor Human | C1 Inhibitor Human | marketed | Plasma-derived protease inhibitor | C1 esterase inhibitor (C1-INH) | Immunology / Rare Genetic Disorders |
Therapeutic area mix
- Immunology / Rare Genetic Disorders · 1
- Neuroscience · 1
- Other · 1
- Pain Management · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
Subscribe to ongoing alerts
Every new pipeline event for GCS Ramsay Santé pour l'Enseignement et la Recherche:
- GCS Ramsay Santé pour l'Enseignement et la Recherche pipeline updates — RSS
- GCS Ramsay Santé pour l'Enseignement et la Recherche pipeline updates — Atom
- GCS Ramsay Santé pour l'Enseignement et la Recherche pipeline updates — JSON
Cite this brief
Drug Landscape (2026). GCS Ramsay Santé pour l'Enseignement et la Recherche — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/gcs-ramsay-sant-pour-l-enseignement-et-la-recherche. Accessed 2026-05-17.